- In line with corporate strategy update in April, ProQR to f…
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.
The RD Fund is changing how the world treats blinding retinal diseases.
Click here to download the January 2022 Outcomes & Outlook Report.
IN THE NEWS
08/12/2022
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Pa…
07/27/2022
Atsena Therapeutics Announces Opening of New Office and Laboratory…
World-class facility supports the company’s growth, and disc…
07/21/2022
Opus Genetics Expands its Leadership Team
Vikram Arora, Ph.D., DABT, appointed Vice President of Non-C…
07/21/2022
RD Fund Announces New Chair, and Expansion of Board of Directors
RD Fund Board member and seasoned ophthalmology leader Adrie…
07/11/2022
Opus Genetics to Present at OIS Retina Innovation Summit 2022
Opus Genetics, a patient-first gene therapy company developi…
06/21/2022
Foundation Fighting Blindness Announces Leadership Changes
Jason Menzo named chief executive officer
Russell Kelley, Ph…
06/15/2022
Nacuity Pharmaceuticals Announces $16.5 Million Series B Financing…
Funds to support advancement of two clinical trials t…
05/11/2022
Opus Genetics Appoints Jennifer Hunt Chief Development Officer
Biopharma clinical development veteran to propel Opus’ AAV-b…
03/08/2022
Foundation Fighting Blindness and InformedDNA Partner to Engage and…
Trial recruitment is enabled by the Foundation Fighting Blin…
02/15/2022
Opus Genetics Appoints Brian Leising Vice President, Manufacturing
20-year biopharma industry veteran to lead manufacturing for…
02/11/2022
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of…
ProQR has published the top-line results from the Phase 2/3 …
01/19/2022
Foundation Fighting Blindness Promotes Jason Menzo to President and…
Media Contact:
Chris Adams
Vice President, Marketing & Com…